top of page

IMVT-1402-2401
Clinical Study
A clinical study by Immunovant Sciences evaluating IMVT-1402, an investigational therapy designed to reduce disease-driving antibodies in people with chronic autoimmune conditions such as CIDP. The trial aims to assess its safety, tolerability, and ability to improve long-term disease control—offering hope for more sustained symptom relief and a better quality of life for patients who have not responded well to existing treatments.
​
To qualify, participants generally must:
​​​​
-
Age: 18 years or older
​
-
Have a confirmed diagnosis of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
​
-
Meet recognized CIDP diagnostic standards (EAN/PNS guidelines), including:
-
Clinical diagnosis of typical CIDP or variants (multifocal or motor CIDP)
-
Electrodiagnostic (nerve test) confirmation supporting CIDP
-
​
-
Be on stable treatment for at least ~3 months, such as:
-
IVIG or SCIG (immunoglobulin therapy), and/or
-
Systemic corticosteroids (stable dose)
-
bottom of page
